Advertisement

Experience with Sandostatin® in Various Groups of Acromegalic Patients

  • A. Stevenaert
  • A. Beckers
  • K. Kovacs
  • E. Bastings
  • M. de Longueville
  • G. Hennen

Abstract

The availability, for clinical use, of the somatostatin analogue SMS 201–995 (Sandostatin®) has opened new doors in the treatment of acromegaly [1, 5, 6]. We report here our experience with Sandostatin used either as a chronic medical therapy or as a preparation to surgery.

Keywords

Growth Hormone Statin Treatment Acromegalic Patient Asymptomatic Gallstone Growth Hormone Profile 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bauer W, Briner U, Doepfner W et al. (1982) SMS 201-995: a very potent and selective octapeptide analogue of Somatostatin with prolonged action. Life Sci 31: 1133CrossRefPubMedGoogle Scholar
  2. 2.
    Beckers A, Stevenaert A, Hennen G (1987) Preoperative and long-term treatment of acromegaly with SMS 201-995. International Symposium on Growth Hormone Basic and Clinical Aspects, Tampa, Florida, June 1987 (abstract)Google Scholar
  3. 3.
    Beckers A, Stevenaert A, Hennen G (1987) SMS 201-995: Therapeutic indications for acromegaly. First European Congress of Endocrinology, Copenhagen, 21–25 June, 1987 (abstract Nos 1–57)Google Scholar
  4. 4.
    Beckers A, Stevenaert A, de Longueville M, Thibaut A, Hennen G (1986) The treatment of acromegaly with the somatostatin analogue SMS 201-995. International Symposium Somatostatin, Madrid, 1986 (abstract)Google Scholar
  5. 5.
    Lamberts SWJ, Oosterom R, Neufeld M, Del Pozo E (1985) The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 60: 1161CrossRefPubMedGoogle Scholar
  6. 6.
    Lamberts SWJ, Uitterlinden P, Verschoor L, van Dongen KJ, Del Pozo E (1985) Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 313: 1576CrossRefPubMedGoogle Scholar
  7. 7.
    Lamberts SWJ, Zweens M, Verschoor L, Del Pozo E (1986) A comparison among the growth hormone-lowering effects in acromegaly of the Somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs. J Clin Endocrinol Metab 63: 16CrossRefPubMedGoogle Scholar
  8. 8.
    Spinas GA, Zapf J, Landolt AM, Stuckmann G, Froesch ER (1987) Pre-operative treatment of 5 acromegalics with a somatostatin analogue: endocrine and clinical observations. Acta Endocrinol (Copenh) 114: 249Google Scholar
  9. 9.
    Stevenaert A, Beckers A, Thibaut A, de Longueville M, Hennen G (1986) Preoperative treatment of acromegaly with SMS 201-995. Acromegaly Centennial Symposium, San Francisco, June 29—July 1 1986 (abstract P18)Google Scholar

Copyright information

© Springer-Verlag, Berlin Heidelberg 1988

Authors and Affiliations

  • A. Stevenaert
    • 1
    • 3
  • A. Beckers
    • 1
    • 3
  • K. Kovacs
    • 1
    • 3
  • E. Bastings
    • 1
    • 3
  • M. de Longueville
    • 2
  • G. Hennen
    • 1
    • 3
  1. 1.Universities of LiègeBelgium
  2. 2.SandozBrusselsBelgium
  3. 3.TorontoCanada

Personalised recommendations